Hematologic Malignancies
November 9
3 min read
Treatment with methylphenidate significantly reduced cancer-related fatigue in patients with hematologic malignancies compared with placebo, according to findings from the randomized, double-blind, crossover MICRO trial reported by Frederiksen et al in the Journal of Clinical Oncology. The improvement exceeded the prespecified threshold for clinical relevance, and treatment was generally well tolerated.